ArticleOncotarget2017
Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Surface Engineering of MXene and Functional Fullerenols for Cancer Biomarker 'eIFLangmuir : the ACS journal of surfaces and colloids · 2025Article
- Proteomic analysis of the urothelial cancer landscape.Nature communications · 2024Article
- Deciphering EIF3D's Role in Immune Regulation and Malignant Progression: A Pan-Cancer Analysis with a Focus on Colon Adenocarcinoma.Journal of inflammation research · 2024Article
- Proteomic analysis of the serum in dogs with pulmonary hypertension secondary to myxomatous mitral valve disease: the preliminary study.Frontiers in veterinary science · 2024Article
- Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.Clinical proteomics · 2023Article
- Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.Biomolecules · 2023Article
- Metabolomic and elemental profiling of blood serum in bladder cancer.Journal of pharmaceutical analysis · 2022Article
- Article
- Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist.Investigative and clinical urology · 2020Review
- Article
- Moesin (Cancers · 2020Article
- Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.Journal of biomedical science · 2020Article
- Reduced eIF3d accelerates HIV disease progression by attenuating CD8+ T cell function.Journal of translational medicine · 2019Article
- Urinary peptide panel for prognostic assessment of bladder cancer relapse.Scientific reports · 2019Article
- Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease.EBioMedicine · 2019Article
- Urinary Proteomics in Predicting Heart Transplantation Outcomes (uPROPHET)-Rationale and database description.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with advanced bladder cancer have poor outcomes, indicating a need for more efficient therapeutic approaches. This study characterizes proteomic changes underlying bladder cancer invasion aiming for the better understanding of disease pathophysiology and identification of drug targets. High resolution liquid chromatography coupled to tandem mass spectrometry analysis of tissue specimens from patients with non-muscle invasive (NMIBC, stage pTa) and muscle invasive bladder cancer (MIBC, stages pT2+) was conducted. Comparative analysis identified 144 differentially expressed proteins between analyzed groups. These included proteins previously associated with bladder cancer and also additional novel such as PGRMC1, FUCA1, BROX and PSMD12, which were further confirmed by immunohistochemistry. Pathway and interactome analysis predicted strong activation in muscle invasive bladder cancer of pathways associated with protein synthesis e.g. eIF2 and mTOR signaling. Knock-down of eukaryotic translation initiation factor 3 subunit D (EIF3D) (overexpressed in muscle invasive disease) in metastatic T24M bladder cancer cells inhibited cell proliferation, migration, and colony formation
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.